UY40028A - Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii - Google Patents

Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii

Info

Publication number
UY40028A
UY40028A UY0001040028A UY40028A UY40028A UY 40028 A UY40028 A UY 40028A UY 0001040028 A UY0001040028 A UY 0001040028A UY 40028 A UY40028 A UY 40028A UY 40028 A UY40028 A UY 40028A
Authority
UY
Uruguay
Prior art keywords
tgf
binding
multispecific
ßrii
binding domain
Prior art date
Application number
UY0001040028A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Mayes
Anna Wilhelmina Geuijen Cecilia
M Stewart Shaun
Wang Liang-Chuan
Original Assignee
Merus Nv
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv, Incyte Corp filed Critical Merus Nv
Publication of UY40028A publication Critical patent/UY40028A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UY0001040028A 2021-11-19 2022-11-18 Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii UY40028A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2029844 2021-11-19

Publications (1)

Publication Number Publication Date
UY40028A true UY40028A (es) 2023-05-31

Family

ID=80625531

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040028A UY40028A (es) 2021-11-19 2022-11-18 Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii

Country Status (18)

Country Link
US (1) US20230159645A1 (https=)
EP (1) EP4433505A1 (https=)
JP (1) JP2024542879A (https=)
KR (1) KR20240101664A9 (https=)
CN (2) CN118265725A (https=)
AR (1) AR127714A1 (https=)
AU (1) AU2022389596A1 (https=)
CA (1) CA3231649A1 (https=)
CL (1) CL2024001410A1 (https=)
CO (1) CO2024006325A2 (https=)
CR (1) CR20240201A (https=)
EC (1) ECSP24039278A (https=)
IL (1) IL312214A (https=)
MX (1) MX2024006018A (https=)
PE (1) PE20241477A1 (https=)
TW (1) TW202328180A (https=)
UY (1) UY40028A (https=)
WO (1) WO2023089083A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240343805A1 (en) * 2023-04-14 2024-10-17 Incyte Corporation USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
AU2018296067B2 (en) * 2017-07-06 2021-06-10 Merus B.V. Binding molecules that modulate a biological activity expressed by a cell
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII

Also Published As

Publication number Publication date
CO2024006325A2 (es) 2024-06-27
CL2024001410A1 (es) 2024-08-30
US20230159645A1 (en) 2023-05-25
WO2023089083A1 (en) 2023-05-25
AU2022389596A1 (en) 2024-05-30
CN118265725A (zh) 2024-06-28
PE20241477A1 (es) 2024-07-17
ECSP24039278A (es) 2024-07-31
KR20240101664A (ko) 2024-07-02
JP2024542879A (ja) 2024-11-18
MX2024006018A (es) 2024-07-29
EP4433505A1 (en) 2024-09-25
AR127714A1 (es) 2024-02-21
IL312214A (en) 2024-06-01
CN119613560A (zh) 2025-03-14
TW202328180A (zh) 2023-07-16
CR20240201A (es) 2024-07-15
CA3231649A1 (en) 2023-05-25
KR20240101664A9 (ko) 2025-12-10

Similar Documents

Publication Publication Date Title
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
MX2020004858A (es) Compuestos moduladores de sting y metodos de elaboracion y uso.
MX392459B (es) Composicion farmaceutica para la prevencion o tratamiento de cancer, que comprende polimorfo cristalino de hexoxido de tetraarsenico
CL2024000560A1 (es) Inhibidores de indolina de kif18a
MX373528B (es) Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos.
MX391406B (es) Aparato para generación de tramas de señal de difusión y método para generación de tramas de señal de difusión utilizando multiplexado por división de capas.
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
MX2024008886A (es) Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
UY33486A (es) Derivados de tetrahidro-pirido-pirimidina
CO2022014673A2 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii
MX2017007598A (es) Dispositivo de generacion de trama de señal de difusion y metodo de generacion de trama de señal de difusion que utiliza limite de tubos de capa fisica de capa de nucleo.
MX392489B (es) Dispositivo multiplexor de señales y método multiplexor de señales que utiliza multiplexión por división de capas.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CL2024003398A1 (es) Inhibidores de pi3kalfa y métodos de uso de los mismos
ECSP24039278A (es) Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii
MX2016006656A (es) Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa.
AR112587A1 (es) Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima
MX2017008842A (es) Aparato y metodo para generacion de tramas de señal de difusion utilizando multiplexado por division de capas.
EA202191502A1 (ru) Способ получения апиксабана
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.
MX2024010977A (es) Composiciones que comprenden aticaprant
CO2024005918A2 (es) Anticuerpos de unión a cd30 y cd3
MX2015015194A (es) Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales.